medical cannabis

medical cannabis
Oren neu dag · CC BY-SA 3.0 · source
Name	Medical cannabis
Caption	Flowering Cannabis plant
Alt	Cannabis bud
Uses	Therapeutic
Legal status	Varies by jurisdiction

medical cannabis Medical cannabis refers to preparations derived from the Cannabis plant used for therapeutic purposes. It intersects clinical practice, policy debates, and biomedical research involving institutions such as World Health Organization, National Institutes of Health, Food and Drug Administration, European Medicines Agency, and national health services like NHS England. Controversies span regulatory frameworks exemplified by laws like the Controlled Substances Act and court rulings such as Gonzales v. Raich.

History

Historical use of Cannabis for medicinal purposes appears in early texts including the Pen Ts'ao Ching and records of the Ancient Egyptian Medicine cited in artifacts from Tutankhamun. In the 19th century, figures like William Brooke O'Shaughnessy and institutions such as the Royal College of Physicians influenced Victorian-era therapeutics. The 20th century saw international treaties like the Single Convention on Narcotic Drugs impede clinical access, while 20th-century personalities including Harry Anslinger and legislative acts like the Marihuana Tax Act of 1937 shaped prohibition. Late 20th- and early 21st-century movements involving organizations such as Americans for Safe Access, campaigns in California, and rulings in courts like the Supreme Court of the United States catalyzed modern legalization and medical program development in places including Canada, Israel, Netherlands, Uruguay, and multiple U.S. state jurisdictions.

Pharmacology and Constituents

Cannabis chemistry includes over a hundred cannabinoids first characterized in chemical studies by researchers such as Raphael Mechoulam at institutions like the Hebrew University of Jerusalem. Principal constituents include delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD); cannabinoid pharmacodynamics engage receptors such as CB1 receptor and CB2 receptor, described in molecular work by laboratories at National Institute on Drug Abuse. Terpenes and flavonoids contribute to the entourage effect debated in literature from journals associated with organizations like the American Medical Association and research centers including Johns Hopkins University. Metabolic pathways involve enzymes like fatty acid amide hydrolase (FAAH) and proteins including monoacylglycerol lipase (MAGL), while pharmacokinetics reference hepatic cytochrome P450 isoforms studied at centers such as Mayo Clinic.

Medical Uses and Evidence

Clinical indications evaluated in randomized controlled trials and systematic reviews by bodies such as the Cochrane Collaboration include chronic pain, chemotherapy-induced nausea and vomiting, spasticity in multiple sclerosis, and epileptic syndromes like Dravet syndrome and Lennox–Gastaut syndrome. Approved pharmaceutical products include formulations reviewed by regulatory agencies: Sativex (nabiximols) approved in nations via agencies like the Medicines and Healthcare products Regulatory Agency and Epidiolex (cannabidiol) licensed by the Food and Drug Administration. Meta-analyses from institutions such as Cochrane and universities including Yale University and University of Toronto report modest benefit for neuropathic pain and refractory epilepsy but call for higher-quality trials as advocated by researchers at University College London and Harvard Medical School.

Administration and Dosage

Routes of administration include inhalation (smoking, vaporization) evaluated in clinical settings at centers like Guy's and St Thomas' NHS Foundation Trust, oral ingestion of oils and capsules as in studies at Karolinska Institutet, oromucosal sprays such as Sativex used in trials at institutions like Imperial College London, and topical preparations assessed in dermatology clinics including at Dermatology Research Centre (UK). Dosage regimens are product-specific and guided by clinical trials conducted by pharmaceutical companies and academic partners such as GW Pharmaceuticals and universities including University of California, San Francisco. Titration protocols and pharmacovigilance frameworks are recommended by agencies like European Monitoring Centre for Drugs and Drug Addiction.

Safety, Side Effects, and Contraindications

Adverse effects documented in cohort studies and surveillance systems at institutions like Centers for Disease Control and Prevention include dizziness, cognitive impairment, psychomotor slowing, and psychiatric events noted in psychiatric research at McLean Hospital. Pulmonary risks associated with combustion were examined in respiratory research at American Thoracic Society, while cardiovascular signals appear in case series reviewed by American College of Cardiology. Contraindications and precautions reference pregnancy studies involving registries such as the European Network of Teratology Information Services and psychiatric risk stratification from clinics like King's College London. Drug–drug interactions mediated by CYP3A4 and CYP2C19 are catalogued in pharmacology resources including the British National Formulary.

Legal and Regulatory Status

Regulation varies internationally: models include national legalization as enacted by the Cannabis Act (Canada), medical program frameworks in states such as California and Florida, parliamentary reforms in Israel, and restrictive scheduling per treaties like the Single Convention on Narcotic Drugs. Regulatory agencies involved include the Food and Drug Administration, European Medicines Agency, and national drug enforcement bodies such as the Drug Enforcement Administration. Policy debates engage legislative bodies including the United States Congress and courts including the European Court of Human Rights. International trade, banking, and research funding are influenced by finance ministries and institutions like the World Bank.

Research and Future Directions

Ongoing research agendas funded by agencies including the National Institutes of Health, European Commission, and foundations such as the Wellcome Trust explore precision cannabinoid therapeutics, genetic determinants investigated in consortia like the Psychiatric Genomics Consortium, and novel delivery systems developed in collaboration with research universities such as MIT and ETH Zurich. Trials addressing long-term outcomes are registered in registries like ClinicalTrials.gov, while translational work in immunology and oncology involves centers such as Dana–Farber Cancer Institute and MD Anderson Cancer Center. Ethical and policy scholarship from think tanks like the Brookings Institution and legal analyses in law schools including Harvard Law School will shape future frameworks for access, research, and clinical integration.

Category:Cannabis